COVID-19 associated mucormycosis surge: A review on multi-pathway mechanisms.
Mohsen PouraziziAtousa HakamifardAlireza PeymanRasoul MohammadiShakiba DehghaniNajmeh TavousiNastaran Sadat HosseiniHamed Azhdari TehraniBahareh Abtahi-NaeiniPublished in: Parasite immunology (2023)
Mucormycosis is a fungal infection caused by moulds from the Mucorales order. Concerns have been mounting due to the alarming increase in severe morbidity and mortality associated with mucormycosis during the COVID-19 pandemic. This condition, known as COVID-19-associated mucormycosis (CAM), has been linked to various environmental, host-related, and medical factors on a global scale. We have categorized the most significant potential risk factors for developing mucormycosis in individuals with a previous history of coronavirus infection into 10 major categories. These categories include acute hyperglycemia, the impact of cytokine release, immune response deficiencies in COVID-19 patients, microvasculopathy and dysfunction of endothelial cells, imbalances in iron metabolism, metabolic acidosis, organ damage resulting from COVID-19, underlying health conditions (such as diabetes), environmental factors, and medical treatments that can be iatrogenic in nature (such as inappropriate glucocorticoid use). Many of these factors can lead to potentially life-threatening infections that can complicate the treatment of COVID-19. Physicians should be vigilant about these factors because early detection of mucormycosis is crucial for effective management of this condition.
Keyphrases
- sars cov
- coronavirus disease
- healthcare
- immune response
- respiratory syndrome coronavirus
- endothelial cells
- oxidative stress
- type diabetes
- public health
- primary care
- mental health
- cardiovascular disease
- early onset
- dendritic cells
- health information
- inflammatory response
- skeletal muscle
- risk assessment
- vascular endothelial growth factor
- glycemic control
- insulin resistance
- replacement therapy
- hepatitis b virus